Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price Target Lowered at Morgan Stanley

Key Points

• Morgan Stanley cut Alnylam’s price target from $300 to $240 while maintaining an “equal weight” rating, implying roughly 43% upside from the prior close.
• Analyst sentiment remains mixed, though the consensus rating is “Moderate Buy” with a $325.50 target; several firms recently lowered targets or ratings amid concerns about near-term demand growth.
• Alnylam’s latest quarter exceeded expectations, with $16.26 adjusted EPS and $1.46 billion in revenue, but shares fell 3.7% to $167.64 and remain near their one-year low.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) had its target price decreased by equities researchers at Morgan Stanley from $300.00 to $240.00 in a report issued on Friday, Benzinga reports. The firm currently has an "equal weight" rating on the biopharmaceutical company's stock. Morgan Stanley's price target would indicate a potential upside of 43.17% from the stock's previous close.

Other research analysts have also issued reports about the stock. Citigroup dropped their price target on shares of Alnylam Pharmaceuticals from $340.00 to $320.00 and set a "buy" rating on the stock in a research report on Wednesday, October 14th. Wells Fargo & Company reduced their target price on Alnylam Pharmaceuticals from $253.00 to $220.00 and set an "equal weight" rating for the company in a report on Friday. Needham & Company LLC decreased their price target on Alnylam Pharmaceuticals from $357.00 to $243.00 and set a "buy" rating for the company in a research report on Thursday. Sanford C. Bernstein cut Alnylam Pharmaceuticals from an "outperform" rating to a "market perform" rating and cut their price objective for the stock from $376.00 to $199.00 in a research report on Friday. Finally, Oppenheimer decreased their target price on Alnylam Pharmaceuticals from $500.00 to $350.00 and set an "outperform" rating for the company in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have given a Hold rating to the company's stock. According to MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $325.50.

Alnylam Pharmaceuticals Trading Down 3.7%

Shares of Alnylam Pharmaceuticals stock traded down $6.36 on Friday, hitting $167.64. 3,318,160 shares of the company's stock traded hands, compared to its average volume of 1,501,652. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 2.99. Alnylam Pharmaceuticals has a one year low of $167.16 and a one year high of $479.79. The company has a fifty day moving average of $237.78 and a two-hundred day moving average of $287.22. The company has a market capitalization of $22.43 billion, a price-to-earnings ratio of 31.19 and a beta of 0.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share for the quarter, beating the consensus estimate of $1.66 by $14.60. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The firm had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.43 billion. During the same quarter in the prior year, the business earned $2.90 earnings per share. The business's quarterly revenue was up 16.7% compared to the same quarter last year. As a group, sell-side analysts expect that Alnylam Pharmaceuticals will post 6.43 earnings per share for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In related news, EVP Bryan Supran sold 1,758 shares of the company's stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $226.88, for a total value of $398,855.04. Following the completion of the transaction, the executive vice president directly owned 12,807 shares in the company, valued at approximately $2,905,652.16. The trade was a 12.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Wellington Management Group LLP boosted its holdings in shares of Alnylam Pharmaceuticals by 9.0% during the 2nd quarter. Wellington Management Group LLP now owns 2,110,407 shares of the biopharmaceutical company's stock valued at $635,296,000 after buying an additional 174,482 shares in the last quarter. Legal & General Group Plc purchased a new position in Alnylam Pharmaceuticals during the 2nd quarter valued at about $278,321,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Alnylam Pharmaceuticals by 7.4% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 727,848 shares of the biopharmaceutical company's stock valued at $219,104,000 after acquiring an additional 50,329 shares during the period. Bank of New York Mellon Corp bought a new stake in Alnylam Pharmaceuticals during the second quarter worth about $148,128,000. Finally, Swiss National Bank grew its holdings in Alnylam Pharmaceuticals by 7.9% in the first quarter. Swiss National Bank now owns 387,720 shares of the biopharmaceutical company's stock worth $128,285,000 after purchasing an additional 28,520 shares during the period. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

More Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Q3 results exceeded expectations. Alnylam reported $16.26 in adjusted earnings per share versus the $1.66 consensus estimate, while revenue rose 16.7% year over year to $1.46 billion, ahead of estimates. The company maintained its fiscal 2026 net product-sales outlook. Alnylam Q3 earnings and revenue results
• Positive Sentiment: Long-term pipeline prospects remain supportive. Alnylam expects $4.2 billion-$4.5 billion in 2026 TTR sales and expanded the TRITON-CM nucresiran heart-disease study to approximately 2,250 patients while maintaining an expected launch timeline around 2030. Alnylam TTR sales and TRITON-CM update
• Neutral Sentiment: Analysts remain divided. Wells Fargo lowered its target to $220 and kept an “equal weight” rating; RBC cut its target to $280 but retained “outperform”; and Needham reduced its target to $243 while maintaining “buy.” These targets still imply substantial potential upside from recent levels.
• Negative Sentiment: Demand growth is the immediate concern. Slower U.S. Amvuttra patient starts and moderating Amvuttra and Onpattro sales growth raised questions about the pace of commercial expansion despite the quarterly beat. Alnylam demand growth concerns
• Negative Sentiment: Broker sentiment weakened. Bernstein downgraded Alnylam to “market perform” with a $199 target, while Stifel cut its rating to “hold” and set a $225 target. The reductions reflect greater caution around near-term growth and valuation.
• Negative Sentiment: Additional risk overhangs remain. An investor law firm announced an investigation related to a prior company disclosure, potentially adding to market uncertainty, although no wrongdoing has been established. Alnylam investor investigation

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company's therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam's marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.